COVID-19, RSV, and influenza immunizations show continued safety and substantial effectiveness against hospitalization across various populations.

Elevated lactate levels and hypotension independently predicted higher in-hospital mortality in critically ill adults with COVID-19.

HCC risk remains after DAA-cured HCV in individuals with HIV, but the annual probability of developing HCC declines over 6 years.

Ablation therapy demonstrated comparable effectiveness for HCC in patients with hepatitis B-related recompensated vs compensated cirrhosis.

Racial and ethnic disparities in pediatric COVID-19 severity were largest among hospitalized Black and Hispanic children with CCCs or government insurance.

In adults aged 18 to 64 years at increased risk for pneumococcal disease due to chronic conditions, the 21-valent pneumococcal conjugate vaccine (V116) is highly immunogenic and well-tolerated, ...

In older adults aged 75 to 79, the bivalent RSV pre-F vaccine demonstrates high effectiveness by significantly reducing hospitalization risk due to RSV-associated acute respiratory infection, ...

Respiratory syncytial virus, rhinovirus/enterovirus, and parainfluenza virus remain the predominant pathogens driving bronchiolitis, pneumonia, and croup hospitalizations among children younger than 5 ...

In an observational study of United States veterans, the 2024 to 2025 COVID-19 vaccine lowered the risk for severe COVID-19 outcomes, providing strong evidence to guide public health discussions ...

WHO director general Dr Tedros Adhanom Ghebreyesus said the agency "is actively supporting Ethiopia to contain the outbreak and treat infected people, and supporting all efforts to address the ...